

OncoTherapy Science, Inc.

April 15, 2015

Announcement of the first-patient enrollment in Japan in phase I clinical trial
of the out-licensed antibody from Immunus Pharma, Inc.

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that KHK6640, an anti-amyloid beta (A β) peptide antibody which was out-licensed from Immunus Pharma, Inc. (President & CEO: Masaharu Mori; hereinafter, “Immunus”; a consolidated subsidiary of OncoTherapy) to Kyowa Hakko Kirin, Ltd. (Head office: Chiyoda-ku, Tokyo, President and CEO: Nobuo Hanai, hereinafter “Kyowa Hakko Kirin”), has been administered to the first patient in phase I clinical trial in Japan following of the phase I clinical trial that was started in Europe last year.

This Clinical Trial aims to confirm the safety and tolerability of this anti-A β peptide antibody in patients with mild to moderate Alzheimer’s disease.

This antibody is a monoclonal antibody which selectively binds to pathological aggregates of A β peptide. A β aggregates are thought to be one of the major factors involved in pathogenesis of Alzheimer’s disease, and this antibody is expected to suppress the progression of the disease.